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Abstract 
Introduction: Lungs are the most exposed organs to different risk factors  like pollution, smoke, infections, 
tuberculosis and allergens. Lungs are covered by parietal and visceral layers of pleura within which pleural fluid is 
present. Aim of the study was to evaluate various histopathological patterns of lung and pleural biopsy in correlation 
with age, sex and immunohistochemistry examination findings.Material and methods: This is a retrospective study 
of three year three months done at Pathology Department, S.S.G. Hospital and Medical College, Baroda from 
October  2016 to  December  2019. In present study, total 169 cases were received for histopathological 
examination, out of which 151 cases were of lung biopsy and 18 cases were of pleural biopsy. Immunohistochemical 
examination was done as and when required.Results:Lung biopsy of  151 cases  were examined. Out of which,  88 
cases (58.3%) were neoplastic, 54(35.8%) cases were non-neoplastic and  9 cases(5.9%) were inconclusive. The 
commonest malignancy was  squamous cell carcinoma. Commonest non-neoplastic lesion was interstitial 
inflammation (6.6%).  Malignancy was seen more  common than inflammatory conditions  in patients presented 
withlung masses in our institute. While out of 18 cases of pleural biopsy,  6 cases(33.3%) were neoplastic and 12 
cases (66.7%) were non-neoplastic. Adenocarcinoma was the most common neoplastic lesion while tuberculosis was 
the most common non-neoplastic pleural lesion.Conclusion:Histopathological examination plays an important role 
in making a correct and accurate diagnosis of various lesions of lung and pleura. Although histopathological 
examination is gold standard, immunohistochemistry can enhance the accuracy of such diagnosis.  
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Introduction 
 
 
Lung cancer is the most commonly diagnosed and fatal 
cancer annually since 1985 in the world. 
Worldwide,there are 1.61 million new cases of lung 
cancer per year, with 1.38 million deaths, making lung 
cancer the leading cause (28%) of cancer-related 
mortality[1]. In India, approximately 63,000 new cases 
of lung cancer are reported each year[2].Most cases of 
squamous cell carcinoma start in the centre of the lungs.  
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These tumors may cause some symptoms such as 
coughing up blood at an earlier stage than tumors on the 
edges of the lungs such as adenocarcinomas[3]. Despite 
the modest improvements in treatments during the last 
few decades, the prognosis of lung cancer is still poor.  
Pleural diseases involve the parietal and visceral pleura 
and may be of infectious, inflammatory, or malignant 
origin, often resulting in pleural effusions. Primary 
pleural malignancies tend to originate from the parietal 
pleura and spread to the visceral pleura, while 
metastatic disease (i.e. bronchogenic carcinoma) starts 
on the visceral pleura and spreads to the parietal pleura 
[4]. Pleural biopsy  have higher diagnostic yield and 
provide better diagnostic sensitivity. In addition, the use 
of immunohistochemistry provides increased diagnostic 
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accuracy[5]. Biopsy not only distinguishes between 
benign and malignant lesions but also helps in typing of 
tumor, so initiation of specific therapy like 
chemotherapy or surgery is possible without 
unnecessary delay. 
 
Material and Methods 
 
This retrospective study was done for the period of  
three years and three months at Department of 
Pathology, S.S.G.Hospital and Medical College,Baroda.  
Here 169  cases of lung and pleural  biopsy specimen  
received in formalin and processed in Yorko automated 
tissue processor. The biopsies  were subjected to 
histopathological examination (H & E stain) and IHC 
panel of stains Pankeratin, CK 5/6, P63,TTF-1, Napsin, 
CK-7, CK-20, Synaptophysin, Chromogranin, CD 45, 
CD 20, CD 5, Ki 67, CD 99, BCL2, Calretinin and 
WT1 wereused for further subtyping whenever 
required. Detailed case history and  clinical examination 
data were studied in correlation with  age, gender and 
histopathological morphology. 
 
 
Results 
 
 In present study, 151 cases of lung biopsy and 18 cases 
of pleural biopsy were received.Among 151 cases of 
lung biopsy, 112 cases (73.6%) were males while 39 
cases (26.4%) were females with male to female ratio of 
2.8:1. Age ranged from 13-83 years with majority of 
cases  were in fifth and sixth decade.(Table 1). Mean 
age was 57.4 year.Transthoracic and bronchoscopy 
guided biopsy were performed where 88 cases were 
neoplastic (58.3%), 63 cases were non-
neoplastic(35.8%), 9 cases(5.9%) were inconclusive. 
There were 26 cases that did not show malignancy in 
suspected clinical and radiological conditions. The most 
common malignancy of lung was squamous cell 
carcinoma i.e. 29 cases (19%) (Figure 1 and Figure 2) 
and the second most common malignancy was 
Adenocarcinoma 27 cases (17.7%)(Figure 3). Both 
malignancy were predominant in male patients. Nine 
cases of  small cell carcinoma were  also more common 
in male patients(Figure 4),which were confirmed 
immunohistochemically(Figure5). 
Among non neoplastic lung lesions, interstitial 
inflammation was the commonest lesion consisting of 
10 cases (6.6%). In present study, immune-
histochemistry was performed in sixty nine  lung biopsy 
and six  pleural biopsy. Among 18 cases of pleural 
biopsy, the age range of the patients were 30-75 years 
with a mean age of 51.4 year.  11 cases (61.1%) were 
males and 7 cases(38.9%) were females. Tuberculosis 
was the most common non neoplastic lesion (Figure 6) 
followed by chronic non specific pleuritis among  
nonneoplastic cases. Majority (33.3%) of malignancy 
were in the age group of  50-70 years. Adenocarcinoma  
was found to be the commonest malignant neoplasm in 
the pleurae  present in all three females followed by 
Non  small cell lung  carcinoma   were all   encountered 
in male patients. The pleural  malignancy was extension 
of underlying lung malignancy which was confirmed by 
immunohistochemical examination. 
Statistical Analysis:Data analysis was done by 
Microsoft Excel worksheet. Descriptive statistics 
evaluated number of cases for percentage of different 
types of lung and pleural lesions and distributed  them 
by age and sex. 
 
Table 1: Distribution of lung and pleural lesions as per different age groups 
Age group Lung lesions Pleural lesions 
1 to 10 year 0 - 
11 to 20 year 1 - 
21to 30 year 8 2 
31 to 40 year 9 4 
41 to 50 year 24 2 
51 to 60 year 45 5 
61 to 70 year 44 4 
71 to 80 year 19 1 
81 to 90 year 1 - 
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Table 2 : Distribution of  various  lesions of lung and pleural biopsy 
 Lung lesions Pleural lesions 
 Cases Percen
tage 
Male Female Number of 
cases 
Percentage Male Female 
Neoplastic 88 58.3% 63 25 6  (33.3%) 2 4 
Adenocarcinoma 27 17.7% 17 10 3 16.6% 0 3 
squamous cell carcinoma 29 19% 23 6 - - - - 
Non small cell carcinoma 14 9.2% 11 3 2 1.3% 2 0 
Non small cell carcinoma,  
SCC 3 1.9% 3 0 - - - - 
Small cell carcinoma 9 5.9% 6 3 - - - - 
Lymphoblatic lymphoma 2 1.3% 1 1 - - - - 
Adenosquamous 
carcinoma 1 0.65% 0 1 - - - - 
Metastatic  1(MGCT*) 0.65% 1 0 1(Breast) 6.6% 0 1 
Carcinoid tumor 1 0.65% 0 1 - - - - 
Synovial sarcoma 1 0.65% 1 0 - - - - 
Non-neoplastic 54 35.8% 41 13 12 66.7% 9 3 
Tuberculous inflammation 3 1.9% 2 1 3 16.6% 2 1 
granulomatous 
inflammation  2 1.3% 2 0 
- - - - 
Pneumonia 2 1.3% 1 1 - - - - 
Interstitial Inflammation 10 6.6%% 7 3 2 1.3% 2 0 
Fibrosis with 
inflammation 3 1.9% 2 1 
- - - - 
Fibrous tissue only 6 3.9% 6 0 - - - - 
No evidence of 
malignancy 26 17.1% 20 6 
7 38.8% 5 2 
No evidence of Tb 2 1.3% 1 1 - - - - 
Inconclusive 9 5.9% 8 1 - - - - 
Total 151  112 39 18  11 7 
Total lung and pleural biopsy 169 
*MGCT-Mixed germ cell tumor 
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Discussion 
 
Lung and pleural biopsy is widely recognized as a 
valuable tool for the diagnosis and management of  
various pathological lesions.Thus tissue sampling  is 
indicated when the diagnosis cannot be obtained by the 
non-invasive techniques and the diagnosis will modify 
the stage of the disease or influence the therapeutic 
strategy. Radiographic diagnosis can be useful, but it 
cannot accurately predicthistology or whether a lesion is 
benign or malignant. Lung biopsy can be performed by 
bronchoscopy guided biopsy, CT guided biopsy or 
excisional biopsy.Pretreatment biopsy of the primary 
tumor is essential for most patients presenting with lung 
masses. A CT-guided percutaneous needle biopsy of the 
lung is commonly used as an outpatient diagnostic 
procedure and is relatively safe, sensitive and accurate 
method of diagnosing benign and malignant lesions as 
well as suitable for obtaining tissue samples of 
sufficient quantity and quality for allowing molecular 
analysis of biomarkers. Image-guided approaches also 
allow biopsy from areas of the tumour feltmost likely to 
harbour viable tumour (i.e., avoiding centrally necrotic 
areas) and representative of whole tumour. Trucut 
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biopsy is very helpful in early diagnosis and less 
invasive as compared to excisional biopsy. A large field 
of research is going on for improving outcome in lung 
cancer.Lung cancer is the leading cause of cancer-
related death worldwide and being increasingly detected 
in India due to increased awareness about lung 
carcinoma and improved diagnostic techniques. In the 
management of lung tumours, accurate diagnosis, using 
a combination of clinical, radiographic and histological 
data is critical inoptimizing outcome. In malignant 
tumour, first approach  should be to classify tumour as 
small cell carcinoma(SCLC) or non- small cell 
carcinoma (NSCLC). The histological subtyping of 
non-small cell lung carcinoma in squamous cell 
carcinoma and adenocarcinoma is also important now 
because the therapeutic approaches,outcome, prognosis 
and survival differs greatly. Inadenocarcinoma, several 
targetable molecular alterations as EGFR mutation, 
KRAS mutation and EML4-ALK rearrangements are 
identified. Targeted therapies hold a considerable 
promise in the treatment of patients with lung 
cancer.Age range in the present study was 13 to 83 
years with the peak in fifth and sixth  decade, which 
was correlated with study by Shah S., Saha A., and 
Mondal SK et al.[6,7,8].  The preponderance of male 
patients (69%) with male to female ratio of 2.8:1 in the 
present study, was comparable to Tan KB et al.  i.e. 
71.1% male patients [9].. In the present study,88 cases 
(58.2%)  were neoplastic, 54 cases (35.7%) were non-
neoplastic and 9 cases (5.9%) were inconclusive.Regina 
Girones et al. studied clinical, histopathological and 
epidemiological characteristics of lung cancer over 
period of 10 years. Among  701 patients91.4% were 
male with  mean age 67.6 year. Squamous cell 
carcinoma prevailed in men (45.5%) and 
adenocarcinoma in women (60.3%) [10]. Manoj Kumar 
Agrawal et al.. studied clinical and pathological profile 
of patients with lung cancer in a tertiary care 
centre,Bareilly. In this retrospective study, 93 
confirmed cases of lung cancer were included. The most 
common histopathological type was squamous cell 
carcinomain 69 cases(74.19%) followed by 
adenocarcinoma in 16 cases(17.20%) and small cell 
carcinoma in 7 cases(7.52%)[11].The study concluded 
that squamous cell carcinoma was the most frequent 
histopathological lesion which also supports results of 
present study. Histopathologically, Carcinoma arising 
from squamous epithelial cells, morphologically 
characterized by proliferation of atypical, often 
pleomorphic squamous cells; graded as well, 
moderately, or poorly differentiated; well differentiated 
carcinomas are usually associated with keratin 
production and presence of intercellular bridges 
between adjacent cells; subtypes include basaloid, clear 
cell type, papillary, small cell nonkeratinizing. Non 
small cell lung Adenocarcinoma of lung shows 
histopathological morphology of malignant cells with 
glandular differentiation, mucin production, or 
pneumocyte marker expression. It shows lepidic, acinar, 
papillary, micropapillary and solid pattern.Non-small 
cell lung cancers comprise 75% of all lung cancers and 
consist of three major histologic types: squamous cell 
carcinoma, adenocarcinoma, and large cell carcinoma. 
Immunohistochemistry is a widely available technique 
that is less challenging and can provide clinically 
meaningful results quickly and cost-efficiently in 
comparison with other techniques. In addition, 
immunohistochemistry allows for the evaluation of 
cellular localization of proteins in the context of tumor 
structure; thus, a greater range of information is 
provided. In an era of precision medicine, pathologists 
are required to classify lung cancer into specific 
subtypes and assess biomarkers relevant to molecular-
targeted therapies[12]. Differential diagnosis between 
adenocarcinoma and squamous cell carcinoma  is 
beneficial because targetable driver genetic alterations 
are mostly identified in adenocarcinoma, and 
inappropriate drugs need to be avoided for patients with 
Squamous cell carcinoma[13].  
 In the current 2015 WHO classification, a solid 
carcinoma without glandular structures or mucin 
production, but with immunohistochemical positivity 
for “adenocarcinoma markers”, i.e., TTF-1 (NKX2-1) 
and/or Napsin A, can be  diagnosed as an 
adenocarcinoma. Similarly, a solid carcinoma without 
keratinization or intercellular bridges, but with 
immunohistochemical positivity for “Squamous cell 
carcinoma markers”, such as p40, CK5/6, and p63, can 
be diagnosed as squamous cell carcinoma.  [14]. 
The  neuroendocrine tumors comprise three subtypes: 
Small cell lung carcinoma (SCLC), large cell 
neuroendocrine carcinoma (LCNEC), and carcinoid 
tumor (typical/atypical) as per classification. Although 
high-grade neuroendocrine tumors (HGNETs), 
comprising SCLCs and LCNECs, belong to the same 
category as carcinoid tumors, their clinical 
characteristics are substantially different. HGNET is an 
aggressive and deadly subtype characterized by patients 
with a history of heavy smoking. In contrast, carcinoid 
tumors usually follow a benign clinical course and 
frequently occur in patients without a history of 
smoking. Despite their different clinical characteristics, 
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these tumors share the features of neuroendocrine 
differentiation. As the definition of LCNEC in the 
WHO classification, the diagnosis of LCNEC requires 
not only neuroendocrine morphology but also 
immunohistochemical expression of at least one of the 
three neuroendocrine markers, i.e., CHGA 
(chromogranin A), SYP (synaptophysin), or NCAM1 
(CD56)[15]. The pleural space is a potential space 
between the visceral and parietal layers of the pleurae. 
The pleural space normally contains 0.1-0.2 ml/kg body 
weight of fluid. Pleural effusion is an abnormal 
accumulation of fluid in the pleural cavity. Pleural 
effusion remains the most common manifestation of 
pleural pathology[16]. Although a variety of clinical 
conditions like heart failure, malignancy, pneumonia, 
tuberculosis may be the cause of a pleural effusion. The 
possibility of a malignant involvement of pleural cavity 
should always be considered in difficult to diagnose 
cases. Indications for percutaneous pleural biopsy 
include undiagnosed pleural effusions and pleural 
thickening or pleural masses[17]. Since percutaneous 
access of the pleural space is relatively simple, 
techniques like pleural biopsy  have become very 
popular. Pleural biopsy were considered as tuberculous 
inflammation when biopsy revealed typical epithelioid 
cell granuloma formation.  In pleura, primary tumor 
may be pulmonary or extrapulmonary. The common 
pulmonary tumors infiltrating in to the pleura are 
squamous cell carcinoma, adenocarcinoma and small 
cell carcinoma. Adenocarcinoma is the most common  
malignancy encountered in the pleural biopsy because 
adenocarcinoma of lung mainly occurs mainly in the 
periphery of lung so local spread  of underlying lung 
tumoris common in pleura. Pandit S, Gaur DS and 
Bhattacharya et al also documented adenocarcinoma as 
the  most common neoplastic lesion in pleura which 
was direct extension from underlying lung parenchyma, 
the  findings are also consistent with  present 
study[17,18,19].Pleural biopsy is a useful and 
minimally invasive procedure.  It is not only cost 
effective but a reasonably safe procedure, which shows 
reasonably good sensitivity and specificity in 
diagnosing primary, as well as metastatic pleural 
malignancies [20]. 
 
Conclusion 
 
Biopsy of lungs and pleurae play an important role for 
correct and accurate diagnosis  and subtyping of various 
pathological lesions. Immunohistochemistry enhance 
the accuracy of such analysis and plays a critical role as  
diagnosing tool. It is strongly indicated when non 
invasive techniques can not conclude or confirm the 
diagnosis and to finalise  therapeutic strategy. 
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